- Home
- JBI vs INBX Comparison
JBI vs INBX Comparison
Compare JBI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBI | INBX |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | JBI | INBX |
|---|---|---|
| Price | $4.80 | $109.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $9.17 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.6M | 586.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $4.26 | $12.80 |
| 52 Week High | $10.80 | $155.29 |
Technical Indicators
Market Signals| Indicator | JBI | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 50.41 |
| Support Level | N/A | $69.30 |
| Resistance Level | $5.66 | $155.29 |
| Average True Range (ATR) | 0.26 | 13.20 |
| MACD | -0.02 | -3.55 |
| Stochastic Oscillator | 46.31 | 23.22 |
Price Performance
Historical ComparisonAbout JBI Janus International Group Inc.
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.